Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis
Esther Byun(University of California, San Francisco), Jorge R. Oksenberg(University of California, San Francisco), Óscar Fernández(Universidad de Málaga), Pablo Villoslada(Hospital Del Mar), Stacy J. Caillier(University of California, San Francisco), Sergio E. Baranzini(University of California, San Francisco), Joanne Wang, Manuel Comabella(Universitat Autònoma de Barcelona), David Brassat, Lisa F. Barcellos(University of California, San Francisco), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 172
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k